We are advancing a portfolio of clinical-stage programs to comprehensively address patient needs in inpatient and outpatient settings by treating a range of multidrug-resistant pathogens. Our team has worked together for over 25 years, completing four regulatory approvals in the past decade.
We continue to make progress, having advanced three products to U.S. Investigational New Drug (IND) application stage during the companyโs first three years of operations. We are combining our deep expertise with Shionogiโs decades of successful infectious disease R&D in Japan to address the unmet medical needs of patients and healthcare professionals and to protect society from serious current and emerging Gram-negative bacterial infections.